Elevance Health has told investors it is holding its full-year 2026 benefit expense ratio guidance at 90.2 percent, plus or minus 50 basis points, a signal that medical utilization and specialty pharmacy costs are tracking in line with what the company built into its pricing for the year.
The guidance reaffirmation came via an 8-K filed with the Securities and Exchange Commission (SEC) on September 10. Company officers said they expect to meet with investors and analysts over the coming weeks and will reaffirm full-year adjusted earnings guidance of at least $27 per diluted share alongside the benefit expense ratio target.
A benefit expense ratio of 90.2 percent means Elevance expects to pay out roughly 90 cents of every premium dollar in medical claims. At that level, the margin available to cover administrative costs, taxes, and profit is thin, and it arrives at precisely the point in the calendar when group health renewals for the fall and early 2027 cycle are being finalized.
Elevance's Q2 2026 results, reported in July, showed a benefit expense ratio of 89.7 percent for the quarter, up 80 basis points year over year. The company attributed the increase to elevated medical cost trends in its government business (Medicaid and Medicare) partially offset by stronger individual ACA performance. The full-year guidance of 90.2 percent implies the second half of 2026 will run heavier than the first, with Q4 historically the highest-cost quarter.
The drivers behind the ratio are not new. Specialty pharmacy costs, led by GLP-1 medications, have been a named factor in Elevance's earnings commentary throughout 2026. The company processes pharmacy claims through its Carelon subsidiary, and specialty pharmacy profitability has been one of the few cost-side offsets in an otherwise pressured environment. Medical cost trend in the government segment has been the primary headwind, driven by Medicaid acuity levels that state reimbursement rates have not fully caught up with.
Elevance is the second-largest US health insurer by membership, with 44.9 million members as of June. Its guidance reaffirmation carries weight as a market indicator because it reflects actual claims experience through mid-year, rather than a projection built on assumptions alone.
Carriers set renewal rates based on what they expect to pay in claims. A benefit expense ratio held steady at 90.2 percent - and tracking to run above that in the back half of the year - means Elevance has budgeted for heavy claims payouts and has priced accordingly. The reaffirmation confirms that assumption has not softened. Brokers heading into fall group renewals with Elevance-affiliated plans are entering a negotiation where the carrier's own public disclosures show claims running at the top of their expected range.
The pattern is not isolated to Elevance. Group health insurer margins thinned across the employer segment in 2025, as medical costs outpaced premium growth for the second consecutive year. The MFA data covering that period showed medical expenses growing 8.6 percent per member per month while premiums earned grew 6.6 percent. That gap is what carriers have been closing through renewal pricing ever since.
